![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: USP48 |
Gene summary for USP48 |
![]() |
Gene information | Species | Human | Gene symbol | USP48 | Gene ID | 84196 |
Gene name | ubiquitin specific peptidase 48 | |
Gene Alias | RAP1GA1 | |
Cytomap | 1p36.12 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q86UV5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84196 | USP48 | EEC-subject3 | Human | Endometrium | EEC | 2.23e-02 | -5.49e-02 | -0.2525 |
84196 | USP48 | GSM5276934 | Human | Endometrium | EEC | 1.92e-03 | -2.09e-01 | -0.0913 |
84196 | USP48 | GSM5276937 | Human | Endometrium | EEC | 4.22e-02 | -1.65e-01 | -0.0897 |
84196 | USP48 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 9.17e-14 | 5.98e-02 | -0.1869 |
84196 | USP48 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.23e-12 | -3.79e-02 | -0.1875 |
84196 | USP48 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 5.44e-15 | -9.17e-02 | -0.1883 |
84196 | USP48 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 9.31e-09 | -1.56e-02 | -0.1934 |
84196 | USP48 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.62e-13 | -1.38e-01 | -0.1917 |
84196 | USP48 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 9.65e-18 | -9.28e-02 | -0.1916 |
84196 | USP48 | LZE4T | Human | Esophagus | ESCC | 2.49e-11 | 4.31e-01 | 0.0811 |
84196 | USP48 | LZE7T | Human | Esophagus | ESCC | 5.93e-07 | 3.59e-01 | 0.0667 |
84196 | USP48 | LZE22T | Human | Esophagus | ESCC | 1.16e-04 | 2.42e-01 | 0.068 |
84196 | USP48 | LZE24T | Human | Esophagus | ESCC | 1.02e-12 | 4.72e-01 | 0.0596 |
84196 | USP48 | P1T-E | Human | Esophagus | ESCC | 3.86e-06 | 3.01e-01 | 0.0875 |
84196 | USP48 | P2T-E | Human | Esophagus | ESCC | 1.72e-32 | 6.67e-01 | 0.1177 |
84196 | USP48 | P4T-E | Human | Esophagus | ESCC | 3.25e-17 | 5.30e-01 | 0.1323 |
84196 | USP48 | P5T-E | Human | Esophagus | ESCC | 1.56e-12 | 1.53e-01 | 0.1327 |
84196 | USP48 | P8T-E | Human | Esophagus | ESCC | 3.59e-29 | 4.61e-01 | 0.0889 |
84196 | USP48 | P9T-E | Human | Esophagus | ESCC | 1.22e-08 | 2.83e-01 | 0.1131 |
84196 | USP48 | P10T-E | Human | Esophagus | ESCC | 1.39e-43 | 9.97e-01 | 0.116 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
GO:00165793 | Esophagus | ESCC | protein deubiquitination | 79/8552 | 139/18723 | 5.23e-03 | 1.97e-02 | 79 |
GO:00706461 | Liver | HCC | protein modification by small protein removal | 91/7958 | 157/18723 | 6.50e-05 | 5.92e-04 | 91 |
GO:00165791 | Liver | HCC | protein deubiquitination | 78/7958 | 139/18723 | 8.13e-04 | 4.87e-03 | 78 |
GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
GO:007064611 | Oral cavity | EOLP | protein modification by small protein removal | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
GO:00165792 | Oral cavity | EOLP | protein deubiquitination | 28/2218 | 139/18723 | 3.29e-03 | 1.90e-02 | 28 |
GO:00706464 | Skin | cSCC | protein modification by small protein removal | 55/4864 | 157/18723 | 7.29e-03 | 3.46e-02 | 55 |
GO:00706465 | Thyroid | PTC | protein modification by small protein removal | 71/5968 | 157/18723 | 3.03e-04 | 2.12e-03 | 71 |
GO:00165794 | Thyroid | PTC | protein deubiquitination | 59/5968 | 139/18723 | 5.50e-03 | 2.50e-02 | 59 |
GO:007064613 | Thyroid | ATC | protein modification by small protein removal | 71/6293 | 157/18723 | 1.59e-03 | 7.99e-03 | 71 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP48 | SNV | Missense_Mutation | novel | c.2039C>G | p.Pro680Arg | p.P680R | Q86UV5 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
USP48 | SNV | Missense_Mutation | novel | c.2755A>G | p.Ile919Val | p.I919V | Q86UV5 | protein_coding | tolerated(0.39) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP48 | SNV | Missense_Mutation | rs778692028 | c.2732N>G | p.Asn911Ser | p.N911S | Q86UV5 | protein_coding | tolerated(0.18) | benign(0.024) | TCGA-AR-A2LM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
USP48 | SNV | Missense_Mutation | c.248G>C | p.Arg83Thr | p.R83T | Q86UV5 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD | |
USP48 | deletion | Frame_Shift_Del | novel | c.2738delG | p.Gly913GlufsTer13 | p.G913Efs*13 | Q86UV5 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
USP48 | deletion | Frame_Shift_Del | novel | c.411delA | p.Asp138IlefsTer83 | p.D138Ifs*83 | Q86UV5 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
USP48 | SNV | Missense_Mutation | rs748095023 | c.2260N>T | p.Arg754Trp | p.R754W | Q86UV5 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
USP48 | SNV | Missense_Mutation | novel | c.1153N>T | p.Gly385Trp | p.G385W | Q86UV5 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
USP48 | SNV | Missense_Mutation | rs765982927 | c.1408N>A | p.Glu470Lys | p.E470K | Q86UV5 | protein_coding | tolerated(0.2) | benign(0.009) | TCGA-EA-A5FO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
USP48 | SNV | Missense_Mutation | c.2747N>A | p.Arg916Gln | p.R916Q | Q86UV5 | protein_coding | deleterious(0.02) | possibly_damaging(0.637) | TCGA-FU-A3HY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |